160 related articles for article (PubMed ID: 21701231)
21. Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?
Hashimoto K; Ueno H; Ikeda M; Kojima Y; Hagihara A; Kondo S; Morizane C; Okusaka T
Oncology; 2009; 77(3-4):217-23. PubMed ID: 19729980
[TBL] [Abstract][Full Text] [Related]
22. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
Song Y; Ji B; Jiang CX; Chen ZM; Yao NH; Mukaida N; Huang H
Pathol Res Pract; 2019 Dec; 215(12):152650. PubMed ID: 31585811
[TBL] [Abstract][Full Text] [Related]
23. Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine.
Sawaki A; Kanemitsu Y; Mizuno N; Takahashi K; Nakamura T; Ioka T; Tanaka S; Nakaizumi A; Salem AA; Ueda R; Yamao K
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1292-7. PubMed ID: 18700899
[TBL] [Abstract][Full Text] [Related]
24. Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer.
Terao T; Kumagi T; Hyodo I; Yokota T; Azemoto N; Miyata H; Kuroda T; Ohno Y; Tanaka Y; Shibata N; Imamura Y; Kanemitsu K; Miyake T; Koizumi M; Hiasa Y;
Medicine (Baltimore); 2021 Oct; 100(43):e27591. PubMed ID: 34713835
[TBL] [Abstract][Full Text] [Related]
25. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.
Vienot A; Beinse G; Louvet C; de Mestier L; Meurisse A; Fein F; Heyd B; Cleau D; d'Engremont C; Dupont-Gossart AC; Lakkis Z; Tournigand C; Bouché O; Rousseau B; Neuzillet C; Bonnetain F; Borg C; Vernerey D
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28383673
[TBL] [Abstract][Full Text] [Related]
26. Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.
Aoyama T; Murakawa M; Katayama Y; Shiozawa M; Ueno M; Morimoto M; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Hepatogastroenterology; 2015; 62(138):472-7. PubMed ID: 25916085
[TBL] [Abstract][Full Text] [Related]
27. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638248
[TBL] [Abstract][Full Text] [Related]
28. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer.
Mitsunaga S; Ikeda M; Shimizu S; Ohno I; Furuse J; Inagaki M; Higashi S; Kato H; Terao K; Ochiai A
Br J Cancer; 2013 May; 108(10):2063-9. PubMed ID: 23591198
[TBL] [Abstract][Full Text] [Related]
29. Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial.
Lambert A; Jarlier M; Gourgou Bourgade S; Conroy T
PLoS One; 2017; 12(9):e0183288. PubMed ID: 28931010
[TBL] [Abstract][Full Text] [Related]
30. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R
Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532
[TBL] [Abstract][Full Text] [Related]
31. The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
Raphael MJ; Raskin W; Habbous S; Tai X; Beca J; Dai WF; Arias J; Forbes L; Gavura S; Biagi JJ; Earle CC; Chan KKW
JAMA Netw Open; 2021 Nov; 4(11):e2133388. PubMed ID: 34779846
[TBL] [Abstract][Full Text] [Related]
32. Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study.
Shukuya T; Yasui H; Boku N; Onozawa Y; Fukutomi A; Yamazaki K; Taku K; Kojima T; Machida N
Jpn J Clin Oncol; 2010 Dec; 40(12):1135-8. PubMed ID: 20656694
[TBL] [Abstract][Full Text] [Related]
33. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.
Hess V; Glimelius B; Grawe P; Dietrich D; Bodoky G; Ruhstaller T; Bajetta E; Saletti P; Figer A; Scheithauer W; Herrmann R
Lancet Oncol; 2008 Feb; 9(2):132-8. PubMed ID: 18249033
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
[TBL] [Abstract][Full Text] [Related]
35. A retrospective analysis of survival factors of high intensity focused ultrasound (HIFU) treatment for unresectable pancreatic cancer.
Ning ZY; Cheng CS; Xie J; Chen QW; Xu LT; Zhuang LP; Zhang CY; Song LB; Shi WD; Zhu XY; Wang P; Wang K; Meng ZQ
Discov Med; 2016 Jun; 21(118):435-45. PubMed ID: 27448780
[TBL] [Abstract][Full Text] [Related]
36. Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis.
Han QL; Zhou YH; Lyu Y; Yan H; Dai GH
J Clin Pharm Ther; 2018 Apr; 43(2):163-169. PubMed ID: 29214667
[TBL] [Abstract][Full Text] [Related]
37. Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy.
Bahra M; Pratschke J; Klein F; Neuhaus P; Boas-Knoop S; Puhl G; Denecke T; Pullankavumkal JR; Sinn M; Riess H; Pelzer U
Pancreas; 2015 Aug; 44(6):930-6. PubMed ID: 25931260
[TBL] [Abstract][Full Text] [Related]
38. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.
Wasan HS; Springett GM; Chodkiewicz C; Wong R; Maurel J; Barone C; Rosbrook B; Ricart AD; Kim S; Spano JP
Br J Cancer; 2009 Oct; 101(7):1162-7. PubMed ID: 19724276
[TBL] [Abstract][Full Text] [Related]
39. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
Farrell JJ; Elsaleh H; Garcia M; Lai R; Ammar A; Regine WF; Abrams R; Benson AB; Macdonald J; Cass CE; Dicker AP; Mackey JR
Gastroenterology; 2009 Jan; 136(1):187-95. PubMed ID: 18992248
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.
Inal A; Kos FT; Algin E; Yildiz R; Berk V; Tugba Unek I; Colak D; Colak D; Kucukoner M; Tamer Elkiran E; Helvaci K; Geredeli C; Dane F; Balakan O; Ali Kaplan M; Gok Durnali A; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Ozkan M; Benekli M; Isikdogan A;
J BUON; 2012; 17(1):102-5. PubMed ID: 22517701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
